Correlation Between Cyclacel Pharmaceuticals and Elevation Oncology

Can any of the company-specific risk be diversified away by investing in both Cyclacel Pharmaceuticals and Elevation Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cyclacel Pharmaceuticals and Elevation Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cyclacel Pharmaceuticals and Elevation Oncology, you can compare the effects of market volatilities on Cyclacel Pharmaceuticals and Elevation Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cyclacel Pharmaceuticals with a short position of Elevation Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cyclacel Pharmaceuticals and Elevation Oncology.

Diversification Opportunities for Cyclacel Pharmaceuticals and Elevation Oncology

0.36

Correlation Coefficient

Cyclacel Pharmaceuticals  Elevation Oncology

Weak diversification

The 3 months correlation between Cyclacel and Elevation is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Cyclacel Pharmaceuticals and Elevation Oncology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Elevation Oncology and Cyclacel Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cyclacel Pharmaceuticals are associated (or correlated) with Elevation Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Elevation Oncology has no effect on the direction of Cyclacel Pharmaceuticals i.e., Cyclacel Pharmaceuticals and Elevation Oncology go up and down completely randomly.

Pair Corralation between Cyclacel Pharmaceuticals and Elevation Oncology

Assuming the 90 days horizon Cyclacel Pharmaceuticals is expected to generate 1.2 times more return on investment than Elevation Oncology. However, Cyclacel Pharmaceuticals is 1.2 times more volatile than Elevation Oncology. It trades about 0.0 of its potential returns per unit of risk. Elevation Oncology is currently generating about -0.11 per unit of risk. If you would invest  729.00  in Cyclacel Pharmaceuticals on December 29, 2024 and sell it today you would lose (185.00) from holding Cyclacel Pharmaceuticals or give up 25.38% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	98.36%
Values	Daily Returns

Cyclacel Pharmaceuticals  vs.  Elevation Oncology

Cyclacel Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cyclacel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental indicators, Cyclacel Pharmaceuticals is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Elevation Oncology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Elevation Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Cyclacel Pharmaceuticals and Elevation Oncology

The main advantage of trading using opposite Cyclacel Pharmaceuticals and Elevation Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cyclacel Pharmaceuticals position performs unexpectedly, Elevation Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elevation Oncology will offset losses from the drop in Elevation Oncology's long position.

The idea behind Cyclacel Pharmaceuticals and Elevation Oncology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.